NCT07124000View on ClinicalTrials.gov

DESTINY-PANTUMOUR04

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

September 18, 2025

Primary Completion Date

March 30, 2028

Study Completion Date

March 30, 2028

Conditions
Adenocarcinoma (NOS)Anal CancerBladder CancerCervical CancerEndometrial CancerEsophageal CancerGall Bladder CancerGastrointestinal Stromal TumourHead and Neck CancerLiver CancerMelanomaMouth CancerNasopharangeal CancerNeuroendocrine, Gastrointestinal CancerOvarian CancerPancreatic CancerProstate CancerRenal Cell CarcinomaSalivary Gland CancerSarcomaSmall Cell Lung CancerTesticular CancerThroat CancerThyroid CancerUrethral CancerVaginal CancerVulvar Cancer
Interventions
DRUG

Trastuzumab deruxtecan

Trastuzumab deruxtecan monotherapy

Trial Locations (8)

27893

RECRUITING

Research Site, Wilson

33065

RECRUITING

Research Site, Coral Springs

33901

RECRUITING

Research Site, Fort Myers

35223

RECRUITING

Research Site, Birmingham

43537

RECRUITING

Research Site, Maumee

44718

RECRUITING

Research Site, Canton

62269

RECRUITING

Research Site, O'Fallon

85122

RECRUITING

Research Site, Casa Grande

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY